A prospective cohort study was conducted on 50 patients who were diagnosed with DLBCL and 30 healthy individuals to assess the sensitivity and specificity of MYD88 and TP53 genetic mutations. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.